DPP4 gene silencing inhibits proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through suppression of the MAPK pathway

Hu, Xiumei; Chen, S.; Xie, Chencheng; Li, Z.; Wu, Zhenzhen; You, Zhijian

doi:10.1007/s40618-020-01455-7

Cited by 20 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current efforts are being made on combinations of siRNA and chemotherapeutic drug delivery systems for the treatment of multidrug resistant cancers [297]. Numerous studies have previously indicated that the above ectoproteases can be "manipulated" by siRNA, resulting in both the in vitro and in vivo inhibition of tumour cell growth and migration, enhanced sensitivity to chemotherapeutic agents, and enhanced survival of mouse xenograft models of cancer [299][300][301][302][303][304][305][306][307][308]. Whether this siRNA strategy opens a new avenue for achieving a "knockout" of cancer-associated ectoproteases is not yet a clinical reality, but deserves attention.…”

Section: Concluding Remarks and Future Directionsmentioning

confidence: 99%

Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Verhulst

Garnier

Meester

et al. 2022

Cancers

View full text Add to dashboard Cite

Cell surface proteases (also known as ectoproteases) are transmembrane and membrane-bound enzymes involved in various physiological and pathological processes. Several members, most notably dipeptidyl peptidase 4 (DPP4/CD26) and its related family member fibroblast activation protein (FAP), aminopeptidase N (APN/CD13), a disintegrin and metalloprotease 17 (ADAM17/TACE), and matrix metalloproteinases (MMPs) MMP2 and MMP9, are often overexpressed in cancers and have been associated with tumour dysfunction. With multifaceted actions, these ectoproteases have been validated as therapeutic targets for cancer. Numerous inhibitors have been developed to target these enzymes, attempting to control their enzymatic activity. Even though clinical trials with these compounds did not show the expected results in most cases, the field of ectoprotease inhibitors is growing. This review summarizes the current knowledge on this subject and highlights the recent development of more effective and selective drugs targeting ectoproteases among which small molecular weight inhibitors, peptide conjugates, prodrugs, or monoclonal antibodies (mAbs) and derivatives. These promising avenues have the potential to deliver novel therapeutic strategies in the treatment of cancers.

show abstract

Section: Concluding Remarks and Future Directionsmentioning

confidence: 99%

Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Verhulst

Garnier

Meester

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…It was reasonable to speculate that the increased epithelial cells ratio and decreased stromal cells ratio in the middle secretory phase may be affected by some transcription genes in TE patients. According to previous research, several upregulated transcription genes such as PAX8 47 and DPP4 48 were identified, which activated the epithelial cells proliferation pathway, in turn promoting cells proliferation and raising the proportion of epithelial cells. In stromal cells, on the one hand, some genes enriched in the biological process of collagen fibril, such as LUM, COL1A1, COL1A2, COL3A1, etc.…”

Section: Discussionmentioning

confidence: 98%

Single‐cell transcriptome analysis uncovers the molecular and cellular characteristics of thin endometrium

Zhang

Chen

et al. 2022

The FASEB Journal

View full text Add to dashboard Cite

Infertility is a social and medical problem around the world and the incidence continues to rise. Thin endometrium (TE) is a great challenge of infertility treatment, even by in vitro fertilization and embryo transfer. It is widely believed that TE impairs endometrium receptivity. However, only a few studies have explained the molecular mechanism. Herein, in order to reveal the possible mechanism, we sampled endometrium from a TE patient and a control volunteer and got a

show abstract

“…Liu et al found elsewhere that the interaction between GPX4 and mTOR signaling modulates ferroptotic cancer cell death (Liu et al, 2021 ). Ferroptosis regulator DPP4 was reported to activate the MAPK pathway in papillary thyroid carcinoma (Hu et al, 2021 ). These studies have indicated that the interaction between ferroptosis and ERBB signaling pathway might be implicated in regulating the TIME of ccRCC.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma

Wang

Chen

Ying

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is one of the tumor types with sensitivity to ferroptosis, and immunotherapy has emerged as a standard pillar for metastatic ccRCC treatment, while it remains largely obscure whether ferroptosis influences the tumor immune microenvironment in ccRCC. Based on available data in The Cancer Genome Atlas, divergent expression profiles of ferroptosis regulators were noted in ccRCC and normal tissues, and we also found that the ferroptosis regulators correlated with the PD-L1 expression. Two independent subtypes were determined by consensus clustering analysis according to the expression level of ferroptosis regulators in ccRCC. Cluster 1 showed lower histological tumor stage and grade, more favorable prognosis, and higher PD-L1 expression compared to cluster 2. CIBERSORT analysis revealed that cluster 2 harbored higher infiltrated levels of CD8+ T cell, Tregs, and T follicular helper cell, while cluster 1 more correlated with the monocyte, M1 macrophage, and M2 macrophage. Gene set enrichment analysis indicated that the ERBB signaling and JAK_STAT signaling pathways were significantly enriched in cluster 1. We subsequently identified CARS as the potentially key immune infiltration-related ferroptosis regulator, whose high expression showed dismal prognosis and was positively correlated with PD-L1 expression in ccRCC. We also verified the upregulation of CARS in ccRCC tissues and cell lines via qRT-PCR method. Additionally, a pan-cancer analysis demonstrated that CARS closely related to the expression of immune checkpoint-related genes (especially PD-L1) and an unfavorable prognosis in diverse cancer types. In summary, our study suggested the crucial role of ferroptosis in immune infiltration of ccRCC, and CARS is a potentially novel prognostic biomarker and potential target for cancer immunotherapy.

show abstract

DPP4 gene silencing inhibits proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through suppression of the MAPK pathway

Cited by 20 publications

References 39 publications

Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Single‐cell transcriptome analysis uncovers the molecular and cellular characteristics of thin endometrium

Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About